Retatrutide, a novel dual stimulator of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) binding site , is showing promising outcomes in initial patient studies. Ongoing research https://thefairlist.com/story11591094/retatrutide-emerging-studies-and-projected-clinical-applications